TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34622845
Drug: A+HA (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: A+HA (20 mL supplement mixture containing 50 mg HA, 750 mg glucosamine, and 250 mg chondroitin)
Study: 32673060
Drug: Hydroxychloroquine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 more days)
Study: 34788698
Drug: Neoadjuvant and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant and concurrent androgen deprivation therapy (ADT) for 6 months starting 4 months before prostate radiation therapy
Study: 34788698
Drug: Concurrent and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent and adjuvant ADT for 6 months starting simultaneously with radiation therapy
Study: 32188492
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus 1g of intravenous calcium gluconate (group 2)
Study: 32188492
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (morphine 0.1 mg/kg + normal saline; group 1)
Study: 33272766
Drug: Waitlist-control (treatment-as-usual)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist-control (treatment-as-usual)
Study: 32901283
Drug: Rotta glucosamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotta glucosamine (DONA powder sachets, 1500 mg/day)
Study: 32901283
Drug: Non-Rotta glucosamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Rotta glucosamine (glucosamine sulphate 1500 mg one-a-day tablet)
Study: 32463382
Drug: Inhalation aromatherapy
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation aromatherapy with lavender and sweet orange
Study: 32390170
Drug: Guided tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided tissue regeneration (GTR) therapy
Study: 35533791
Drug: Short-course IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course IV antibiotics (2 weeks)
Study: 35533791
Drug: Standard-course IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-course IV antibiotics (6 weeks)
Study: 35109491
Drug: Small group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small group music therapy (GMT)
Study: 32363616
Drug: Synbiotic supplementation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic supplementation (500 mg/day)
Study: 33931405
Drug: Immune therapy
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune therapy
Study: 32067293
Drug: Mindful Yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindful Yoga Intervention (MYI) added to Treatment as Usual (TAU)
Study: 34915084
Drug: Neurofilament light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurofilament light chain dosage (NF‐L) at thresholds of 500 pg/ml and 1,200 pg/ml added to the modified ESICM/ERC 2021 algorithm.
Study: 34915084
Drug: Unmodified ESICM/ERC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unmodified ESICM/ERC 2021 algorithm without NF‐L.
Study: 34915084
Drug: Neurofilament light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurofilament light chain (NF‐L) values for good versus poor outcomes.
Study: 32846798
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (TXA) administration [1 g] before skin incision
Study: 34002563
Drug: Gel plaster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel plaster
Study: 39112892
Drug: Enriched Music-supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enriched Music-supported Therapy (eMST)
Study: 34979513
Drug: Levetiracetam (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (250 mg to a maximum of 1,500 mg)
Study: 34979513
Drug: Levetiracetam (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (250 mg to a maximum of 1,500 mg) and Placebo
Study: 32311006
Drug: Chronic physical
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic physical illness and functions of daily living
Study: 32097392
Drug: Argon plasma
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argon plasma coagulation (APC) treatment offered in 96% of cases
Study: 33852730
Drug: Text messaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text messaging intervention (TMI) in addition to group counseling, nicotine patches, and written material; Duration: 6 weeks
Study: 33852730
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (group counseling, nicotine patches, and written material)
Study: 34903344
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents (DES) used in 76% of BVS-ISR patients
Study: 34098214
Drug: High-protein group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein group (HPG) - 25% daily calorie of protein
Study: 34098214
Drug: Regular-protein group
Normalized name: PROTEIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular-protein group (RPG) - 15% daily calorie of protein
Study: 34134881
Drug: Extended-release injectable
Normalized name: Exenatide for Extended-Release Injectable Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release injectable naltrexone before release (BR)
Study: 34134881
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to treatment after release (AR)
Study: 32345253
Drug: SMAQ (Simplified
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMAQ (Simplified Medication Adherence Questionnaire) at T1 (baseline)
Study: 32345253
Drug: SMAQ (Simplified
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMAQ (Simplified Medication Adherence Questionnaire) at T2 (follow-up)
Study: 32147082
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment plus conventional treatment
Study: 33957854
Drug: Influvac® Tetra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influvac® Tetra (subunit, inactivated influenza vaccine)
Study: 33957854
Drug: VaxiFlu‐4 (split
Approvals — FDA: no, EMA: no, PMDA: no
Description: VaxiFlu‐4 (split virion, inactivated influenza vaccine)
Study: 35973226
Drug: Novel antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel antimicrobial wound gel system
Study: 35353636
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) using gallium aluminum arsenide (GaAlAs) laser with parameters: wavelength of 810 nm, power of 0.5% ± 20% W, energy density of 4 J/cm2.
Study: 35353636
Drug: Ibuprofen (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (control group).
Study: 33351989
Drug: 1.0% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% chlorhexidine gluconate solution preoperatively
Study: 35737699
Drug: Laser-based cavity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser-based cavity preparation with acid etching (test group I, n = 21)
Study: 35737699
Drug: Laser-based cavity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser-based cavity preparation without acid etching (test group II, n = 21)
Study: 35737699
Drug: Conventional diamond
Normalized name: diamond
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diamond burs preparation (control group, n = 33)
Study: 33453391
Drug: Niraparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib (300 mg/day or 200 mg/day based on body weight and platelet count)
Study: 33610422
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg resveratrol daily for 3 months
Study: 33610422
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg placebo daily for 3 months
Study: 36045021
Drug: CD20-targeting agents
Normalized name: HuMax-CD20
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CD20-targeting agents
Study: 36045021
Drug: No CD20-targeting
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No CD20-targeting agents
Study: 35258443
Drug: Meropenem 2
Normalized name: meropenem 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 2 g every 8 hours (TID)
Study: 35258443
Drug: Meropenem 2
Normalized name: meropenem 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 2 g TID plus rifampin at 20 mg/kg once daily
Study: 35258443
Drug: Meropenem 1
Normalized name: meropenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 1 g TID
Study: 35258443
Drug: Meropenem 3
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem 3 g once daily
Study: 32860696
Drug: High frequency
Normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL SOLUTION [enMotion Foam High Frequency Use]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High frequency chest wall oscillation and conventional chest physical therapy (breathing exercises, early ambulation, and cough training) thrice per week for 8 weeks
Study: 32860696
Drug: Traditional chest
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional chest physical therapy (breathing exercises, early ambulation, and cough training) thrice per week for 8 weeks
Study: 34237210
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy with temozolomide followed by 6 cycles of adjuvant temozolomide (arm A)
Study: 35246214
Drug: Opioid-sparing therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid-sparing therapies
Study: 35246214
Drug: Opioid-based therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid-based therapies
Study: 32068667
Drug: Low concentration
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low concentration desipramine titrated to reach a serum concentration level of 15 to 65 ng/mL
Study: 32068667
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) and active placebo medication (benztropine mesylate, 0.125 mg)
Study: 32068667
Drug: Active benztropine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active benztropine placebo medication
Study: 33734127
Drug: Intravenous diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diclofenac sodium (1.5 mg/kg)
Study: 32212810
Drug: 30 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2 cisplatin weekly (Arm A)
Study: 32212810
Drug: 100 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/m2 cisplatin once every 3 weeks (Arm B)
Study: 35720170
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BRJ) 115 ml daily for 7 days
Study: 35720170
Drug: Green leafy
Normalized name: Green tea leaf
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green leafy vegetable juice 250 ml daily for 7 days
Study: 36377523
Drug: Vortioxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine treatment
Study: 32044511
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) using anthracycline-based regimen without taxanes
Study: 33389369
Drug: topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: topical timolol 0.5% (n = 16)
Study: 33389369
Drug: topical brimonidin
Normalized name: brimonidine Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical brimonidin (n = 15)
Study: 33389369
Drug: oral acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral acetazolamide 250 mg (n = 14)
Study: 33389369
Drug: intravenous mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous mannitol (1.5 gr/kg) (n = 16)
Study: 33389369
Drug: no intraocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: no intraocular pressure-lowering medication (n = 13)
Study: 32131742
Drug: Potentially inappropriate
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially inappropriate medications (PIMs)
Study: 33174383
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) 3 times weekly for 8 weeks
Study: 33174383
Drug: Manual acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual acupuncture (MA) 3 times weekly for 8 weeks
Study: 33174383
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture (SA) 3 times weekly for 8 weeks
Study: 33351101
Drug: VKA regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: VKA regimen with triple-Antithrombotic therapy
Study: 32706640
Drug: Postradiation chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postradiation chemotherapy (PCV; procarbazine, lomustine (CCNU), and vincristine)
Study: 35751032
Drug: Resistance 'exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance 'exercise snacks' performed once daily (n=9)
Study: 35751032
Drug: Resistance 'exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance 'exercise snacks' performed twice daily (n=10)
Study: 35751032
Drug: Resistance 'exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance 'exercise snacks' performed thrice daily (n=9)
Study: 36364828
Drug: Food for
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food for special medical purposes composed of omega‐3 fatty acids (500 mg), leucine (2.5 g), and probiotic Lactobacillus paracasei PS23
Study: 35126899
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (supplemented with Western medical treatment)
Study: 35132421
Drug: Oral camostat
Normalized name: collagen hemostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral camostat mesylate, 200 mg po four times a day for 7 days
Study: 32406224
Drug: Single rehabilitative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single rehabilitative treatment (ST)
Study: 32406224
Drug: Group rehabilitative
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group rehabilitative treatment (GT)
Study: 33170444
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) - 10 individual, weekly sessions preoperative
Study: 33556230
Drug: Atezolizumab and
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab and bevacizumab combination
Study: 36380312
Drug: MEDI3902 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI3902 1500 mg (single intravenous dose)
Study: 36380312
Drug: MEDI3902 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI3902 1500 mg
Study: 34331755
Drug: Osteopathic manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manual therapy (OMT)
Study: 34220324
Drug: Low bilirubin
Normalized name: bilirubin preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low bilirubin group (serum bilirubin≤9.7umol/L, n=753)
Study: 34220324
Drug: High bilirubin
Normalized name: bilirubin preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High bilirubin group (serum bilirubin>9.7umol/L, n=739)
Study: 32709657
Drug: Individualised, pharmacist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised, pharmacist led support service focusing on medication adherence and physical comorbidity management.
Study: 35592991
Drug: Online therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online therapy management system (TMS) with wearable auricular vagus nerve stimulation device
Study: 33040814
Drug: Physiological seawater
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological seawater nasal irrigation combined with oral desloratadine citrate disodium
Study: 33040814
Drug: Oral desloratadine
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral desloratadine citrate disodium
Study: 33599087
Drug: Adapted Dialectical
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted Dialectical Behaviour Therapy (aDBT-ID)
Study: 32899022
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment arm (vitamin K2 isoform 360 mcg 3 times weekly for 18 months)
Study: 32985288
Drug: Chamomile gel
Normalized name: Chamomile
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile gel (8.35%)
Study: 32926847
Drug: Text parsing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Text parsing tool for identifying poor medication adherence
Study: 32926847
Drug: Self-reported medication
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported medication adherence assessment
Study: 35192860
Drug: 75-mg clopidogrel
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75-mg clopidogrel daily (n=80)
Study: 35192860
Drug: 3.75-mg prasugrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75-mg prasugrel daily (n=84)
Study: 33925704
Drug: Cooked ham
Normalized name: egg shell, cooked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooked ham enriched with antioxidants (100 g/d)
Study: 33691439
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (EA + dyclonine hydrochloride)
Study: 33798487
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of moxidectin
Study: 33798487
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of moxidectin
Study: 33798487
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of moxidectin
Study: 33798487
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of moxidectin
Study: 33798487
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of moxidectin
Study: 33798487
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg of moxidectin
Study: 36864979
Drug: Allopurinol 300
Normalized name: allopurinol 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 300 mg twice daily
Study: 35689370
Drug: Focused Extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Focused Extracorporeal Shock Wave Therapy (fESWT) at the lumbar and sacral spine (0.15 mJ/mm², 1000 pulses, 4 Hz)
Study: 34534863
Drug: Injection extended-release
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection extended-release naltrexone (XR-NTX), delivered approximately every 28 days
Study: 34534863
Drug: Daily sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sublingual buprenorphine-naloxone (BUP-NX)
Study: 34534863
Drug: Estimated individualized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estimated individualized treatment rule for OUD
Study: 32487150
Drug: Magnesium oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium oxide (500 mg thrice daily)
Study: 32487150
Drug: Naldemedine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naldemedine (0.2 mg once daily)
Study: 35488084
Drug: lenrispodun 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: lenrispodun 1.0 mg
Study: 35488084
Drug: lenrispodun 10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: lenrispodun 10.0 mg
Study: 32784346
Drug: IV vortioxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV vortioxetine 25 mg plus daily oral vortioxetine 10 mg
Study: 32784346
Drug: IV placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV placebo plus daily oral placebo
Study: 36379827
Drug: Modified Vocal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Vocal Function Exercises with reduced requirement for maximally sustained phonation (midpoint group MG)
Study: 33648515
Drug: Empagliflozin (EMPA)
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin (EMPA) 10 mg/day in humans
Study: 33648515
Drug: Empagliflozin (EMPA)
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin (EMPA) 30 mg/kg in mice
Study: 32894959
Drug: Pectoral nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pectoral nerve block with 30 ml ropivacaine 0.375% (Pecs group)
Study: 32894959
Drug: Thoracic paravertebral
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic paravertebral block with 20 ml ropivacaine 0.5% (TPVB group)
Study: 32087795
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate 300 mg once a day
Study: 33735884
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m2 and carboplatin AUC 5 every 3 weeks
Study: 33735884
Drug: Paclitaxel 80
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80 mg/m2 on day 1, day 8, and day 15 with carboplatin AUC 5 every 4 weeks for 4 cycles
Study: 38188539
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (0.5 mg/kg)